Drug-Induced Movement Disorders
Postgrad Med 180, 1971, Sept., North,R., 1971
A Young Woman With Hypertonia, Severe Scoliosis, and Encephalopathy
JAMA Neurol 81:83-84, Hua,L.,et al, 2024
Withdrawing Amantadine in Dyskinetic Patients with Parkinson Disease
Neurol 82:300-307, Ory-Magne, F.,et al, 2014
Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Clinicopath Conf, Dopamine-Responsive-Dystonia Caused by a Mutation in the GCH1 Gene
NEJM 355:831-839, Case 26-2006, 2006
Treatments of Parkinson Disease
Arch Neurol 60:1680-1684, Shults,C.W., 2003
Subthalamic DBS Replaces Levodopa in Parkinson's Disease
Neurol 58:396-401, Vingerhoets,F.J.G.,et al, 2002
A Five-Year Study of the Incidence of Dyskinesia in Patients With Early Parkinson's Disease who were Treated with Ropinirole or Levodopa
NEJM 342:1484-1491, Rascol,O.,et al, 2000
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease
JAMA 284:1931-1938,1971, Parkinson Study Group, 2000
Catechol-O-Methyltransferase Inhibitors for Treatment of Parkinson's Disease
Lancet 351:1221-1222, Nutt,J.G., 1998
Early Dopaminergic Drug-Induced Hallucinations in Parkinsonian Patients
Neurol 51:811-814, Goetz,C.G.,et al, 1998
Long-Term Follow-Up of Levodopa Responsiveness in Generalized Dystonia
Arch Neurol 55:1320-1323, Dewey,R.B.,et al, 1998
Subcotical Arteriosclerotic Encephalopathy (Binswangers Disease)
, Ghika,J. &Bogousslavsky, J., 1998
Low-Dose Clozapine Improves Dyskinesias in Parkinson's Disease
Neurol 48:658-662, Durif,F.,et al, 1997
Managing the Late Complications of Parkinson's Disease
Neurol 49:549-557, Waters,C.H., 1997
Drug Treatment of Parkinson's Disease
BMJ 310:575-579, Quinn,N., 1995
Low-Dose Clozapine in the Treatment of Levodopa-Induced Mental Disturbances in Parkinson's Disease
Neurol 45:432-434, Rabey,J.M.,et al, 1995
Increased Incidence of Levodopa Therapy Following Metoclopramide Use
JAMA 274:1780-1782, Avorn,J.,et al, 1995
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Olanzapine in the Treatment of Dopaminomimetic Psychosis in Patients with Parkinson's Disease
Neurol 47:1085-1087, Wolters,W.Ch.,et al, 1992
Dopa-Responsive Dystonia:Long-Term Treatment Response and Prognosis
Neurol 41:174-181, Nygaard,T.G.,et al, 1991
Young-Onset Parkinson's Disease:A Clinical Review
Neurol 41:168-173, Golbe,L.I., 1991
Early Development of Levodopa-Induced Dyskinesias and Response Fluctuations in Young-Onset Parkinson's Disease
Neurol 41:202-205, Kostic,V., 1991
Levodopa-Induced Dyskinesia:Review, Observations, and Speculations
Neurol 40:340-345, Nutt,J.G., 1990
Respiratory Dysfunction Due to L-Dopa Therapy for Parkinsonism:Diagnosis Using Serial Pulmonary Function Tests
Am J Med 89:109-114, Zupnick,H.M.,et al, 1990
Dopa Responsive Dystonia:A Treatable Condition Misdiagnosed as Cerebral Palsy
BMJ 298:1019-1020, Boyd,K.&Patterson,V., 1989
Diffuse Lewy Body Disease:Clinical Features in 15 Cases
JNNP 52:709-717, Byrne,E.J., 1989
L-Dopa-Induced Respiratory Disturbance in Parkinson's Disease Suppressed by Tiapride
Neurol 35:235-237, DeKeyser,J.,et al, 1985
Onset & End-of-dose Levodopa-induced Dyskinesias
Arch Neurol 35:261, Lhermitte,F.,et al, 1978
Studies with Bromocriptine Part 2. Double-blind Comparison with Levodopa in Idiopathic Parkinsonism
Neurol 26:511, Kartzinel,R.,et al, 1976
Huntington's Chorea-Deficiency of Y-Aminobutynic Acid in Brain
NEJM 288:337, 1973, 289:104, 1973, 292:10295., Perry,T.,et al, 1975
Catecholamines & Neurologic Diseases
NEJM 293:274, Moskowitz,M.A.,et al, 1975
Levodopa-Induced Myoclonus
Arch Neurol 32:331-334, Klawans,H.L., 1975
Implications of Amphetamine-Induced Stereotyped Behavior as a Model for Tardive Dyskinesias
Arch Gen Psychiat 27:502-507, Rubovits,R.,et al, 1972